AbCellera Biologics (ABCL) Return on Sales (2020 - 2024)
AbCellera Biologics' Return on Sales history spans 5 years, with the latest figure at 5.14% for Q3 2024.
- For the quarter ending Q3 2024, Return on Sales fell 80.0% year-over-year to 5.14%, compared with a TTM value of 5.14% through Sep 2024, down 257.0%, and an annual FY2024 reading of 5.65%, down 180.0% over the prior year.
- Return on Sales for Q3 2024 was 5.14% at AbCellera Biologics, down from 4.8% in the prior quarter.
- The five-year high for Return on Sales was 0.78% in Q4 2020, with the low at 5.14% in Q4 2023.
- Average Return on Sales over 5 years is 1.73%, with a median of 0.45% recorded in 2020.
- Year-over-year, Return on Sales soared 414bps in 2022 and then crashed -460bps in 2023.
- Tracing ABCL's Return on Sales over 5 years: stood at 0.78% in 2020, then tumbled by -44bps to 0.43% in 2021, then crashed by -422bps to 1.39% in 2022, then plummeted by -270bps to 5.14% in 2023, then changed by 0bps to 5.14% in 2024.
- Per Business Quant, the three most recent readings for ABCL's Return on Sales are 5.14% (Q3 2024), 4.8% (Q2 2024), and 4.11% (Q1 2024).